Identifying Circulating Breast Cancer Cells in Women With Metastatic Breast Cancer



Status:Completed
Conditions:Breast Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:August 2007
End Date:January 2014

Use our guide to learn which trials are right for you!

A Feasibility Study of a Novel Technique to Identify Circulating Breast Cancer Cells in Patients With Metastatic Breast Cancer

RATIONALE: Studying samples of blood and pleural or peritoneal fluid from patients with
metastatic breast cancer in the laboratory may help doctors identify biomarkers related to
breast cancer and learn more about how breast cancer begins and spreads in the body.

PURPOSE: This research study is looking at a new way of identifying circulating breast
cancer cells in blood and in pleural or peritoneal fluid in women with metastatic breast
cancer.

OBJECTIVES:

Primary

- To compare identification of circulating breast cancer cells (CBCCs) in blood or
pleural or peritoneal fluid by a novel technique using stem cell marker retinaldehyde
dehydrogenase (ALDH) and surface antigen expression (CD44+, CD24-) to the standard
technique using the CellSearch® system in women with metastatic breast cancer.

Secondary

- To determine whether CBCCs have the potential to grow into metastatic lesions.

OUTLINE: Patients undergo sample collection to help develop a new technique using stem cell
marker retinaldehyde dehydrogenase (ALDH) and surface antigen expression (CD44+, CD24-) in
isolating circulating breast cancer cells (CBCCs) from blood and pleural or peritoneal
fluid. Blood may also be drawn to measure the number of circulating tumor cells using the
standard CellSearch® system.

Mononuclear cells are isolated by density centrifugation. Cells are stained against surface
antigens that provide specific expression patterns for CBCCs (CD44, CD24). Cells are
analyzed on a fluorescence activated cell sorting (FACS) Calibur flow cytometer and
sequentially gated (ALDHhigh→CD44+ vs CD24-/low or CD44+ vs CD24-/low→ALDHhigh) for
detection of CBCCs. For further confirmation of epithelial origin, ALDHhighCD44+CD24-/low
cells are isolated using a FACSAria flow sorter, cytocentrifuged onto glass slides then
stained for the expression of epithelial-specific cytokeratins 5, 8, 14, 18 and 19 by
standard immunohistochemical techniques. Using the phenotype that is found to most highly
enrich for epithelial cells, cells are isolated by FACS and assayed for clonogenic growth.

DISEASE CHARACTERISTICS:

- Histologically confirmed adenocarcinoma of the breast

- Metastatic disease (stage IV)

- Hormone receptor status not specified

PATIENT CHARACTERISTICS:

- Female

- Menopausal status not specified

PRIOR CONCURRENT THERAPY:

- Not specified
We found this trial at
1
site
Baltimore, Maryland 21231
410-955-6190
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins The name Johns Hopkins has become synonymous...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials